Balanced news tone
News Sentiment
DVYSR sentiment intelligence
Devyser Diagnostics AB (publ) news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
55
Balanced news tone
6 relevant articles
News tone and price action are not far from neutral.
73/100 classification confidence.
directly relevant articles
high-authority source matches
+1.8% over one week, -31.1% over four weeks, trend inactive, and below fair value.
Invitation to audiocast for Devyser’s Q2 report 2026
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
73/100 classification
One-week reaction
1.8%
Price digesting
Trend fit
Trend inactive
-31.1% over four weeks
Fair value
-40.8%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
2
Neutral
4
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
TradingView
Direct company coverage
Invitation to audiocast for Devyser’s Q2 report 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 08:00
- Source
- TradingView
marketscreener.com
Direct company coverage
Devyser Diagnostics: Affaersvaerlden remains long-term positive on the stock
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 03 Jul 2026 13:28
- Source
- marketscreener.com
marketscreener.com
Direct company coverage
Devyser Diagnostics AB Announces Group Preliminary Sales Results for the Second Quarter and First Half of the Year 2026
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 02 Jul 2026 07:00
- Source
- marketscreener.com
simplywall.st
Direct company coverage
We Think Devyser Diagnostics (STO:DVYSR) Can Easily Afford To Drive Business Growth
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 18 Apr 2026 07:00
- Source
- simplywall.st
Market source
Direct company coverage
A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks’ Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 Apr 2026 07:00
- Source
- Market source
Cision News
Direct company coverage
Devyser enters agreement with Thermo Fisher Scientific for commercialization of Devyser’s post-transplant NGS products
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Apr 2023 07:00
- Source
- Cision News